Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Soluble stroma-related biomarkers of pancreatic cancer.

Resovi A, Bani MR, Porcu L, Anastasia A, Minoli L, Allavena P, Cappello P, Novelli F, Scarpa A, Morandi E, Falanga A, Torri V, Taraboletti G, Belotti D, Giavazzi R.

EMBO Mol Med. 2018 Jun 25. pii: e8741. doi: 10.15252/emmm.201708741. [Epub ahead of print]

2.

BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.

Wunderle M, Gass P, Häberle L, Flesch VM, Rauh C, Bani MR, Hack CC, Schrauder MG, Jud SM, Emons J, Erber R, Ekici AB, Hoyer J, Vasileiou G, Kraus C, Reis A, Hartmann A, Lux MP, Beckmann MW, Fasching PA, Hein A.

Breast Cancer Res Treat. 2018 Aug;171(1):85-94. doi: 10.1007/s10549-018-4797-8. Epub 2018 May 3.

PMID:
29725888
3.

Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol.

Marzagalli M, Moretti RM, Messi E, Marelli MM, Fontana F, Anastasia A, Bani MR, Beretta G, Limonta P.

Sci Rep. 2018 Jan 12;8(1):587. doi: 10.1038/s41598-017-19057-4.

4.

Modeling Cytostatic and Cytotoxic Responses to New Treatment Regimens for Ovarian Cancer.

Falcetta F, Bizzaro F, D'Agostini E, Bani MR, Giavazzi R, Ubezio P.

Cancer Res. 2017 Dec 1;77(23):6759-6769. doi: 10.1158/0008-5472.CAN-17-1099. Epub 2017 Sep 26.

PMID:
28951463
5.

Evaluation of a Marker Clip System in Sonographically Guided Core Needle Biopsy for Breast Cancer Localization Before and After Neoadjuvant Chemotherapy.

Schulz-Wendtland R, Dankerl P, Bani MR, Fasching PA, Heusinger K, Lux MP, Jud SM, Rauh C, Bayer CM, Schrauder MG, Beckmann MW, Uder M, Brehm B, Loehberg CR.

Geburtshilfe Frauenheilkd. 2017 Feb;77(2):169-175. doi: 10.1055/s-0042-124191.

6.

Correction: Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.

Pretto F, Ghilardi C, Moschetta M, Bassi A, Rovida A, Scarlato V, Talamini L, Fiordaliso F, Bisighini C, Damia G, Bani MR, Piccirillo R, Giavazzi R.

Oncotarget. 2016 Jun 21;7(25):38973. doi: 10.18632/oncotarget.9971. No abstract available.

7.

PO-44 - Tissue factor pathway inhibitor-2 (TFPI-2) is cleaved by PRSS3: implication for tumor endothelial cells migration.

Ghilardi C, Anastasia A, Avigni R, Lupi M, Giavazzi R, Bani MR.

Thromb Res. 2016 Apr;140 Suppl 1:S192-3. doi: 10.1016/S0049-3848(16)30177-3. Epub 2016 Apr 8.

PMID:
27161730
8.

Touch Imprint Cytology and Stereotactically-Guided Core Needle Biopsy of Suspicious Breast Lesions: 15-Year Follow-up.

Schulz-Wendtland R, Fasching PA, Bani MR, Lux MP, Jud S, Rauh C, Bayer C, Wachter DL, Hartmann A, Beckmann MW, Uder M, Loehberg CR.

Geburtshilfe Frauenheilkd. 2016 Jan;76(1):59-64.

9.

Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2.

Ghilardi C, Silini A, Figini S, Anastasia A, Lupi M, Fruscio R, Giavazzi R, Bani MR.

Oncotarget. 2015 Sep 29;6(29):28389-400. doi: 10.18632/oncotarget.4949.

10.

Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.

Pinessi D, Ostano P, Borsotti P, Bello E, Guffanti F, Bizzaro F, Frapolli R, Bani MR, Chiorino G, Taraboletti G, Resovi A.

Connect Tissue Res. 2015;56(5):355-63. doi: 10.3109/03008207.2015.1045065. Epub 2015 Jun 15.

PMID:
25943461
11.

Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.

Pretto F, Ghilardi C, Moschetta M, Bassi A, Rovida A, Scarlato V, Talamini L, Fiordaliso F, Bisighini C, Damia G, Bani MR, Piccirillo R, Giavazzi R.

Oncotarget. 2015 Feb 20;6(5):3043-54.

12.

Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations.

Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, Ghilardi C, Perego P, Fruscio R, Buda A, Milani R, Ostano P, Chiorino G, Bani MR, Damia G, Giavazzi R.

Cancer Res. 2014 Dec 1;74(23):6980-90. doi: 10.1158/0008-5472.CAN-14-0274. Epub 2014 Oct 10.

13.

Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.

Borsotti P, Ghilardi C, Ostano P, Silini A, Dossi R, Pinessi D, Foglieni C, Scatolini M, Lacal PM, Ferrari R, Moscatelli D, Sangalli F, D'Atri S, Giavazzi R, Bani MR, Chiorino G, Taraboletti G.

Pigment Cell Melanoma Res. 2015 Jan;28(1):73-81. doi: 10.1111/pcmr.12319. Epub 2014 Oct 13.

PMID:
25256553
14.

Time and Resources Needed to Document Patients with Breast Cancer from Primary Diagnosis to Follow-up - Results of a Single-center Study.

Lux MP, Sell CS, Fasching PA, Seidl-Ertel J, Bani MR, Schrauder MG, Jud SM, Loehberg CR, Rauh C, Hartmann A, Schulz-Wendtland R, Strnad V, Beckmann MW.

Geburtshilfe Frauenheilkd. 2014 Aug;74(8):743-751.

15.

Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis.

Fasching PA, Ekici AB, Wachter DL, Hein A, Bayer CM, Häberle L, Loehberg CR, Schneider M, Jud SM, Heusinger K, Rübner M, Rauh C, Bani MR, Lux MP, Schulz-Wendtland R, Hartmann A, Beckmann MW.

Geburtshilfe Frauenheilkd. 2013 Dec;73(12):1228-1235.

16.

Health utilities in gynecological oncology and mastology in Germany.

Hildebrandt T, Thiel FC, Fasching PA, Graf C, Bani MR, Loehberg CR, Schrauder MG, Jud SM, Hack CC, Beckmann MW, Lux MP.

Anticancer Res. 2014 Feb;34(2):829-35.

PMID:
24511019
17.

Comprehensive visualization of paresthesia in breast cancer survivors.

Jud SM, Hatko R, Maihöfner C, Bani MR, Schrauder MG, Lux MP, Beckmann MW, Bani G, Eder I, Fasching PA, Loehberg CR, Rauh C, Hein A.

Arch Gynecol Obstet. 2014 Jul;290(1):135-41. doi: 10.1007/s00404-014-3164-1. Epub 2014 Feb 5.

PMID:
24496514
18.

Assessment of breast volume changes during human pregnancy using a three-dimensional surface assessment technique in the prospective CGATE study.

Bayer CM, Bani MR, Schneider M, Dammer U, Raabe E, Haeberle L, Faschingbauer F, Schneeberger S, Renner SP, Fischer D, Schulz-Wendtland R, Fasching PA, Beckmann MW, Jud SM.

Eur J Cancer Prev. 2014 May;23(3):151-7. doi: 10.1097/CEJ.0b013e3283651ccb.

PMID:
24100511
19.

Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors.

Lux MP, Bayer CM, Loehberg CR, Fasching PA, Schrauder MG, Bani MR, Häberle L, Engel A, Heusinger K, Tänzer T, Radosavac D, Scharl A, Bauerfeind I, Gesslein J, Schulte H, Overbeck-Schulte B, Beckmann MW, Hein A.

Breast Cancer Res Treat. 2013 Jun;139(2):429-40. doi: 10.1007/s10549-013-2557-3. Epub 2013 May 14.

PMID:
23670130
20.

Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis.

Loehberg CR, Almstedt K, Jud SM, Haeberle L, Fasching PA, Hack CC, Lux MP, Thiel FC, Schrauder MG, Brunner M, Bayer CM, Hein A, Heusinger K, Heimrich J, Bani MR, Renner SP, Hartmann A, Beckmann MW, Wachter DL.

Breast Cancer Res Treat. 2013 Apr;138(3):899-908. doi: 10.1007/s10549-013-2460-y. Epub 2013 Mar 12.

PMID:
23479421
21.

Financing of certified centers: a willingness-to-pay analysis.

Thiel FC, Scharl A, Hildebrandt T, Kotziabassis E, Schrauder MG, Bani MR, Müller A, Hauzenberger T, Loehberg CR, Jud SM, Fasching PA, Hartmann A, Schulz-Wendtland R, Strnad V, Beckmann MW, Lux MP.

Arch Gynecol Obstet. 2013 Mar;287(3):495-509. doi: 10.1007/s00404-012-2572-3. Epub 2012 Oct 19.

PMID:
23080545
22.

Factors influencing breast changes after pregnancy.

Rauh C, Faschingbauer F, Haeberle L, Jud SM, Heusinger K, Fasching PA, Goecke TW, Rajakaruna N, Voigt F, Bani MR, Lux MP, Renner SP, Loehberg CR, Hartmann A, Schulz-Wendtland R, Beckmann MW, Bayer CM.

Eur J Cancer Prev. 2013 May;22(3):259-61. doi: 10.1097/CEJ.0b013e328359cb81.

PMID:
23022745
23.

Shared decision-making in breast cancer: discrepancy between the treatment efficacy required by patients and by physicians.

Thiel FC, Schrauder MG, Fasching PA, Löhberg CR, Bani MR, Häberle L, Tänzer T, Radosavac D, Scharl A, Bauerfeind I, Gesslein J, Schulte H, Overbeck-Schulte B, Beckmann MW, Lux MP.

Breast Cancer Res Treat. 2012 Oct;135(3):811-20. doi: 10.1007/s10549-012-2218-y. Epub 2012 Aug 30.

PMID:
22933029
24.

Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts.

Moschetta M, Pretto F, Berndt A, Galler K, Richter P, Bassi A, Oliva P, Micotti E, Valbusa G, Schwager K, Kaspar M, Trachsel E, Kosmehl H, Bani MR, Neri D, Giavazzi R.

Cancer Res. 2012 Apr 1;72(7):1814-24. doi: 10.1158/0008-5472.CAN-11-1919. Epub 2012 Mar 5.

25.

Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection.

Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, Bayer CM, Bani MR, Richter S, Adamietz BR, Wenkel E, Rauh C, Beckmann MW, Fasching PA.

PLoS One. 2012;7(1):e29770. doi: 10.1371/journal.pone.0029770. Epub 2012 Jan 5.

26.

Health Services Research and Health Economy - Quality Care Training in Gynaecology, with Focus On Gynaecological Oncology.

Lux MP, Fasching PA, Loehberg CR, Jud SM, Schrauder MG, Bani MR, Thiel FC, Hack CC, Hildebrandt T, Beckmann MW.

Geburtshilfe Frauenheilkd. 2011 Dec;71(12):1046-1055. Review.

27.

Use of Tomosynthesis in Intraoperative Digital Specimen Radiography - Is a Reduction of Breast Re-excision Rates Possible?

Schulz-Wendtland R, Dilbat G, Bani MR, Lux MP, Meier-Meitinger M, Wenkel E, Schwab S, Beckmann MW, Uder M, Adamietz B.

Geburtshilfe Frauenheilkd. 2011 Dec;71(12):1080-1084.

28.

Breast Cancer Risk - Genes, Environment and Clinics.

Fasching PA, Ekici AB, Adamietz BR, Wachter DL, Hein A, Bayer CM, Häberle L, Loehberg CR, Jud SM, Heusinger K, Rübner M, Rauh C, Bani MR, Lux MP, Schulz-Wendtland R, Hartmann A, Beckmann MW.

Geburtshilfe Frauenheilkd. 2011 Dec;71(12):1056-1066.

29.

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.

Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR, Schrauder M, Kahmann L, Lux MP, Strehl JD, Hartmann A, Dimmler A, Beckmann MW, Wachter DL.

BMC Cancer. 2011 Nov 14;11:486. doi: 10.1186/1471-2407-11-486.

30.

Accuracy of radiological tumour size assessment and the risk for re-excision in a cohort of primary breast cancer patients.

Meier-Meitinger M, Rauh C, Adamietz B, Fasching PA, Schwab SA, Haeberle L, Hein A, Bayer CM, Bani MR, Lux MP, Hartmann A, Wachter DL, Uder M, Schulz-Wendtland R, Beckmann MW, Heusinger K.

Eur J Surg Oncol. 2012 Jan;38(1):44-51. doi: 10.1016/j.ejso.2011.10.008. Epub 2011 Oct 26.

PMID:
22032911
31.

Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients.

Beckmann MW, Brucker C, Hanf V, Rauh C, Bani MR, Knob S, Petsch S, Schick S, Fasching PA, Hartmann A, Lux MP, Häberle L.

Onkologie. 2011;34(7):362-7. doi: 10.1159/000329601. Epub 2011 Jun 15.

PMID:
21734422
32.

Breast volumetry using a three-dimensional surface assessment technique.

Koch MC, Adamietz B, Jud SM, Fasching PA, Haeberle L, Karbacher S, Veit K, Schulz-Wendtland R, Uder M, Beckmann MW, Bani MR, Heusinger K, Loehberg CR, Cavallaro A.

Aesthetic Plast Surg. 2011 Oct;35(5):847-55. doi: 10.1007/s00266-011-9708-x. Epub 2011 Apr 13.

PMID:
21487916
33.

Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression.

Ruffini F, Failla CM, Orecchia A, Bani MR, Dorio AS, Fortes C, Zambruno G, Graziani G, Giavazzi R, D'Atri S, Lacal PM.

Br J Dermatol. 2011 May;164(5):1061-70. doi: 10.1111/j.1365-2133.2010.10200.x.

PMID:
21198538
34.

Assessment of breast cancer tumour size using six different methods.

Meier-Meitinger M, Häberle L, Fasching PA, Bani MR, Heusinger K, Wachter D, Beckmann MW, Uder M, Schulz-Wendtland R, Adamietz B.

Eur Radiol. 2011 Jun;21(6):1180-7. doi: 10.1007/s00330-010-2016-z. Epub 2010 Dec 30.

PMID:
21191794
35.

Assessment of mammographic density before and after first full-term pregnancy.

Loehberg CR, Heusinger K, Jud SM, Haeberle L, Hein A, Rauh C, Bani MR, Lux MP, Schrauder MG, Bayer CM, Helbig C, Grolik R, Adamietz B, Schulz-Wendtland R, Beckmann MW, Fasching PA.

Eur J Cancer Prev. 2010 Nov;19(6):405-12. doi: 10.1097/CEJ.0b013e32833ca1f4.

PMID:
20700056
36.

Dual targeting of tumor and endothelial cells by gonadotropin-releasing hormone agonists to reduce melanoma angiogenesis.

Moretti RM, Mai S, Montagnani Marelli M, Bani MR, Ghilardi C, Giavazzi R, Taylor DM, Martini PG, Limonta P.

Endocrinology. 2010 Oct;151(10):4643-53. doi: 10.1210/en.2010-0163. Epub 2010 Aug 4.

37.

Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.

Hammer C, Fasching PA, Loehberg CR, Rauh C, Ekici AB, Jud SM, Bani MR, Beckmann MW, Strick R, Niesler B.

Pharmacogenomics. 2010 Jul;11(7):943-50. doi: 10.2217/pgs.10.67.

PMID:
20602613
38.

The era of centers: the influence of establishing specialized centers on patients' choice of hospital.

Lux MP, Fasching PA, Schrauder M, Löhberg C, Thiel F, Bani MR, Hildebrandt T, Grün AH, Beckmann MW, Goecke TW.

Arch Gynecol Obstet. 2011 Mar;283(3):559-68. doi: 10.1007/s00404-010-1398-0. Epub 2010 Feb 24.

PMID:
20180128
39.

Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype.

Silini A, Ghilardi C, Ardinghi C, Bernasconi S, Oliva P, Carraro F, Naldini A, Bani MR, Giavazzi R.

Clin Exp Metastasis. 2010;27(1):43-53. doi: 10.1007/s10585-009-9301-8. Epub 2009 Dec 20.

PMID:
20084489
40.

Neurokinin 1 receptor gene polymorphism might be correlated with recurrence rates in endometriosis.

Renner SP, Ekici AB, Maihöfner C, Oppelt P, Thiel FC, Schrauder M, Uenluehan N, Bani MR, Strissel PL, Strick R, Beckmann MW, Fasching PA.

Gynecol Endocrinol. 2009 Nov;25(11):726-33. doi: 10.3109/09513590903159631.

PMID:
19903051
41.

Pain perception and detailed visual pain mapping in breast cancer survivors.

Jud SM, Fasching PA, Maihöfner C, Heusinger K, Loehberg CR, Hatko R, Rauh C, Bani H, Lux MP, Beckmann MW, Bani MR.

Breast Cancer Res Treat. 2010 Jan;119(1):105-10. doi: 10.1007/s10549-009-0485-z. Epub 2009 Jul 30.

PMID:
19641989
42.

Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients.

Wiesner FG, Magener A, Fasching PA, Wesse J, Bani MR, Rauh C, Jud S, Schrauder M, Loehberg CR, Beckmann MW, Hartmann A, Lux MP.

Breast. 2009 Apr;18(2):135-41. doi: 10.1016/j.breast.2009.02.009. Epub 2009 Apr 1.

PMID:
19342238
43.

Are Certified Breast Centers Cost-Effective?

Beckmann MW, Bani MR, Loehberg CR, Hildebrandt T, Schrauder MG, Wagner S, Fasching PA, Lux MP.

Breast Care (Basel). 2009;4(4):245-250. Epub 2009 Aug 14.

44.

Correlates of the desire for improved cosmetic results after breast-conserving therapy and mastectomy in breast cancer patients.

Bani MR, Beckmann K, Engel J, Lux MP, Rauh C, Eder I, Bani A HA, Breuel C, Bach A, Beckmann MW, Fasching PA.

Breast. 2008 Dec;17(6):640-5. doi: 10.1016/j.breast.2008.05.004. Epub 2008 Jul 1.

PMID:
18595700
45.

Factors correlating with reexcision after breast-conserving therapy.

Bani MR, Lux MP, Heusinger K, Wenkel E, Magener A, Schulz-Wendtland R, Beckmann MW, Fasching PA.

Eur J Surg Oncol. 2009 Jan;35(1):32-7. doi: 10.1016/j.ejso.2008.04.008. Epub 2008 Jun 9.

PMID:
18539425
46.

Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.

Fasching PA, Kollmannsberger B, Strissel PL, Niesler B, Engel J, Kreis H, Lux MP, Weihbrecht S, Lausen B, Bani MR, Beckmann MW, Strick R.

J Cancer Res Clin Oncol. 2008 Oct;134(10):1079-86. doi: 10.1007/s00432-008-0387-1. Epub 2008 Apr 4.

PMID:
18389280
47.

Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer.

Schrauder M, Frank S, Strissel PL, Lux MP, Bani MR, Rauh C, Sieber CC, Heusinger K, Hartmann A, Schulz-Wendtland R, Strick R, Beckmann MW, Fasching PA.

J Cancer Res Clin Oncol. 2008 Aug;134(8):873-82. doi: 10.1007/s00432-008-0355-9. Epub 2008 Feb 9.

PMID:
18264724
48.

Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.

Fasching PA, Loehberg CR, Strissel PL, Lux MP, Bani MR, Schrauder M, Geiler S, Ringleff K, Oeser S, Weihbrecht S, Schulz-Wendtland R, Hartmann A, Beckmann MW, Strick R.

Breast Cancer Res Treat. 2008 Nov;112(1):89-98. Epub 2007 Nov 30.

PMID:
18049890
49.

Changes in satisfaction in patients with gynaecological and breast malignancies: an analysis with the Socio-Economic Satisfaction and Quality of Life questionnaire.

Fasching PA, Nicolaisen-Murmann K, Lux MP, Bender HG, Ackermann S, Beckmann MW, Bani MR.

Eur J Cancer Care (Engl). 2007 Nov;16(6):508-16.

PMID:
17944765
50.

Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds.

Giavazzi R, Bani MR, Taraboletti G.

Cancer Metastasis Rev. 2007 Dec;26(3-4):481-8. Review.

PMID:
17896168

Supplemental Content

Support Center